Targeting KRAS in Pancreatic Cancer

被引：11

作者：

Cowzer, Darren ^{[1
]}

Zameer, Mohammed ^{[1
]}

Conroy, Michael ^{[1
]}

Kolch, Walter ^{[2
,3
]}

Duffy, Austin G. ^{[1
]}

机构：

[1] Mater Misericordiae Univ Hosp, Dept Med Oncol, Dublin D07R2WY, Ireland

[2] Univ Coll Dublin, Sch Med, Syst Biol Ireland, Belfield D04E1W1, Dublin, Ireland

[3] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Belfield D04E1W1, Dublin, Ireland

来源：

JOURNAL OF PERSONALIZED MEDICINE | 2022年 / 12卷 / 11期

基金：

爱尔兰科学基金会;

关键词：

KRAS; pancreas cancer; targeted therapy; CELL LUNG-CANCER; ONCOGENIC KRAS; SOLID TUMORS; AMG; 510; INHIBITOR; THERAPY; COMBINATION; ADENOCARCINOMA; IMMUNOTHERAPY; GEMCITABINE;

D O I：

10.3390/jpm12111870

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock. Here, we review these innovations in therapies that target RAS signaling in pancreatic cancer from a clinical point of view. A number of promising approaches are currently in clinical trials or in clinical development. We focus on small-molecule drugs but also discuss immunotherapies and tumor vaccines.

引用

页数：11

共 50 条

[1] Targeting KRAS in pancreatic cancer
Stickler, Sandra
Rath, Barbara
Hamilton, Gerhard
ONCOLOGY RESEARCH, 2024, 32 (05) : 799 - 805
[2] Targeting KRAS for pancreatic cancer treatment
Der, Channing J.
CANCER RESEARCH, 2024, 84 (17)
[3] Targeting Oncogenic KRAS in Pancreatic Cancer
不详
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (04) : 569 - 569
[4] PANCREATIC CANCER Exosomes for targeting KRAS in the treatment of pancreatic cancer
Buscail, Louis
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (11) : 636 - 637
[5] Exosomes for targeting KRAS in the treatment of pancreatic cancer
Louis Buscail
Nature Reviews Gastroenterology & Hepatology, 2017, 14 : 636 - 638
[6] Targeting KRAS in pancreatic cancer: new drugs on the horizon
Sahar F. Bannoura
Md. Hafiz Uddin
Misako Nagasaka
Farzeen Fazili
Mohammed Najeeb Al-Hallak
Philip A. Philip
Bassel El-Rayes
Asfar S. Azmi
Cancer and Metastasis Reviews, 2021, 40 : 819 - 835
[7] Chemoprevention of pancreatic cancer by targeting Kras mutations for apoptosis
Zagorodna, Oksana
Wang, Huamin
Wu, Xiangwei
CANCER RESEARCH, 2015, 75
[8] Targeting KRAS in pancreatic cancer: new drugs on the horizon
Bannoura, Sahar F.
Uddin, Md. Hafiz
Nagasaka, Misako
Fazili, Farzeen
Al-Hallak, Mohammed Najeeb
Philip, Philip A.
El-Rayes, Bassel
Azmi, Asfar S.
CANCER AND METASTASIS REVIEWS, 2021, 40 (03) : 819 - 835
[9] Inhibitor combinations targeting KRAS effector signaling in KRAS-mutant pancreatic cancer
Cox, Adrienne D.
Goodwin, Craig M.
Bryant, Kirsten L.
Dagliyan, Irem
George, Samuel D.
Lucas, Kelly E.
Gautam, Prson
Wennerberg, Krister
Der, Channing J.
CANCER RESEARCH, 2018, 78 (13)
[10] Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, Sushrut
LeBleu, Valerie S.
Sugimoto, Hikaru
Yang, Sujuan
Ruivo, Carolina F.
Melo, Sonia A.
Lee, J. Jack
Kalluri, Raghu
NATURE, 2017, 546 (7659) : 498 - +

← 1 2 3 4 5 →